LAENNEC

Phase 3Biologic

GGreen Cross Wellbeing

LAENNEC is one of 29 biologic programs targeting Shoulder Impingement Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Shoulder Impingement SyndromeActive, not recruiting

Non-Alcoholic Fatty Liver DiseaseRecruiting

Shoulder Impingement SyndromePreclinical

Active, not recruiting

Non-Alcoholic Fatty Liver DiseasePhase 3

Recruiting

Competition

Competitive Landscape

31 competitors in Non-Alcoholic Fatty Liver Disease

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

6 2

Avandia

Jazz Pharmaceuticals

Approved

1 3

Actigall

Calciferol

Uloric

Crestor

Bayer Aspirin

Januvia

ZZydus Therapeutics Inc.

Approved

3 9

Jardiance

Boehringer Ingelheim

Approved

2 10

Glucophage

EMD Serono

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Non-Alcoholic Fatty Liver Disease

NCT06493799

Clinical

Trials by Indication[1]

Liver Disease1 trial

Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.

Completed·GGreen Cross Wellbeing·Phase 2·NCT05532124·49 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop

Recruiting·GGreen Cross Wellbeing·Phase 3·NCT06493799·226 enrolled

Shoulder Impingement Syndrome1 trial

Investigator Initiated Trial to Evaluate Efficacy and Safety of LAENNEC (Human Placenta Hydrolysate) Administered by Ultrasonography Guided Subacromial Bursa Injection in Patients With Shoulder Impingement Syndrome

Completed·GGreen Cross Wellbeing·N/A·NCT05528705·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for LAENNEC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LAENNEC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LAENNEC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Green Cross Wellbeing company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: GGreen Cross Wellbeing

LAENNEC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Liver Disease1 trial

Non-Alcoholic Fatty Liver Disease1 trial

Shoulder Impingement Syndrome1 trial

References

Drug Info

Quick Facts

Related News